PROK logo

ProKidney Corp. Class A Ordinary Shares


PROK: ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's own cells isolated from the patient intended for treatment. Its lead product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's own renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease.


Show PROK Financials

Consumer Interest
SEC Filings

Recent trades of PROK by members of U.S. Congress

Quiver Logo

No Congress Trading data for this ticker

Congress Trading Dashboard

Recently reported changes by institutional investors

Quarterly net insider trading by PROK's directors and management

Government lobbying spending instances

Quiver Logo

No Corporate Lobbying instances for this ticker

Corporate Lobbying Dashboard
U.S. Patents

New patents grants

  • Patent Title: Renal cell populations and uses thereof Jun. 28, 2022
  • Patent Title: Bioactive renal cells for the treatment of chronic kidney disease Sep. 21, 2021
Government Contracts

Federal grants, loans, and purchases

Quiver Logo

No Government Contracts for this ticker

Government Contracts Dashboard

Number of mentions of PROK in WallStreetBets Daily Discussion


Recent insights relating to PROK

CNBC Recommendations

Recent picks made for PROK stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in PROK

Corporate Flights

Flights by private jets registered to PROK